TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04943003

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Initially, a measuring tape will be used to make the markings and measurements necessary for placing the electrodes.~Regarding neurostimulation, the tDCS device is simple and portable, consisting of four main components: two electrodes (anode and cathode), an ammeter (electric current intensity meter), a potentiometer (voltage controller between electrodes) and a set of batteries. We will use the TCT-Research Neurostimulator, developed by Trans Cranial Technologies (Hong Kong, China), Regarding the protocols, the Active tDCS group will receive active tDCS for 30 minutes and for 5 consecutive days, in two weeks, with an anode positioned on the left DLPFC and a cathode electrode placed on the right supraorbital area. The 10-20 International EEG system will be taken as a reference. The current intensity will be defined from computational modeling, using Nuclear Magnetic Resonance (NMR) to estimate and individualize the dose to be administered.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Initially, a measuring tape will be used to make the markings and measurements necessary for placing the electrodes.~Regarding neurostimulation, the tDCS device is simple and portable, consisting of four main components: two electrodes (anode and cathode), an ammeter (electric current intensity meter), a potentiometer (voltage controller between electrodes) and a set of batteries. We will use the TCT-Research Neurostimulator, developed by Trans Cranial Technologies (Hong Kong, China), Regarding the protocols, the Active tDCS group will receive active tDCS for 30 minutes and for 5 consecutive days, in two weeks, with an anode positioned on the left DLPFC and a cathode electrode placed on the right supraorbital area. The 10-20 International EEG system will be taken as a reference. The current intensity will be defined from computational modeling, using Nuclear Magnetic Resonance (NMR) to estimate and individualize the dose to be administered.
Study: NCT04853355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone 50 mg
Description: Add Spironolactone 50 mg to previous regimen
Study: NCT05614973

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional method
Description: The conventional method utilizes a 18G biopsy gun to acquire three or more tissue cores with the corresponding number of liver capsule punctures. Plugging of the biopsy needle track is not performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coaxial method with needle-track plugging
Description: The coaxial method utilizes a 17G coaxial needle with 18G biopsy gun to acquire three or more tissue cores with a single liver capsule puncture. Biopsy needle track is plugged using a slurry of gelatin particles (EGgel S Plus 2000-4000 μm).
Study: NCT05203523

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial alternative current stimulation (tACS)
Description: A light electrical current will be applied to the scalp of the participants via 2 electrodes, while the participants performs cognitive exercises with the guidance of a trained research assistant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive exercises
Description: Participant will perform memory and learning games/tasks through Mind Triggers app on an IPad. Participants will be guided by a highly trained research assistant.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: cognitive exercises
Description: Participant will perform memory and learning games/tasks through Mind Triggers app on an IPad. Participants will be guided by a highly trained research assistant.
Study: NCT01400789

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Dosage form- Subcutaneous Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: Dosage form- Subcutaneous Injection
Study: NCT04423861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: Patients will receive nitazoxanide 600 mg BID for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive matching placebo BID for 7 days.
Study: NCT05496751

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low amount, low intensity exercise
Description: Participants will exercise under supervision. Exercise dose will vary by amount and intensity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low amount, high intensity exercise
Description: Participants will exercise under supervision. Exercise dose will vary by amount and intensity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High amount, high intensity exercise
Description: Participants will exercise under supervision. Exercise dose will vary by amount and intensity
Study: NCT04665167

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Body image exposure
Description: Exposure therapy is a key element of evidence-based cognitive behaviour therapy for eating disorders . Body image exposure intervention involves deliberate, planned, and systematic exposure to the body image. Participants will be asked to stand so that they can see their whole body - far enough back. Participants will be asked to look at their bodies on screen. Participants will be continually encouraged by the facilitator for looking at and talking about the body parts.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-compassion
Description: The self-compassion intervention condition consists of Neff's self-compassion exercises. These exercises are part of the self-compassion intervention condition. Meditation text used in this study is obtained from the following link https://self-compassion.org/category/exercises/.
Study: NCT05745454

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER2-E-CART cells
Description: E-CAR-T is a novel second-generation CAR-T product targeting HER2 protein
Study: NCT05452590

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided wire-in-needle technique for central venous catheter placement
Description: The guidewire will be connected to the needle. The IJV will be punctured in a long-axis in-plane approach. When the needle tip enters the IJV, the guidewire will be advanced through the needle into the IJV under continuous ultrasound visualization. The needle will then be removed. The correct guidewire position in the IJV will be confirmed in the long-axis and short-axis view. Afterwards, the second guidewire will be placed in the same IJV approximately 1-2 centimeters distal to the fist guidewire using the same technique. The correct guidewire position in the IJV will be confirmed in the long-axis and short-axis view again.
Study: NCT05355025

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WiserAD
Description: See Arms

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention control
Description: See Arms
Study: NCT05459285

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 14028 injection
Description: 14028 injection, single dose, s.c. injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: dulaglutide injection
Description: dulaglutide injection(TRULICITY®), single dose, s.c. injection
Study: NCT05583201

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KD-496
Description: Autologous genetically modified anti-NKG2DL/CLDN18.2 CAR transduced T cells
Study: NCT04775251

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upward rotation exercise
Description: Treatment for correction of depressed scapular Alignment by exercise ( Upward Rotation Exercises) for 6 weeks.
Study: NCT04575103

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antipsychotic
Description: Antipsychotic treatment \>0.5 DDD
Study: NCT04915651

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gallbladder Cryoablation
Description: Percutaneous cryoablation of the gallbladder.
Study: NCT05922020

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen gas
Description: Administration of Oxygen by inhalation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen gas
Description: Administration of Oxygen by inhalation
Study: NCT06033157

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapist supervised training
Description: A 12 week physiotherapist supervised training program. The patient will receive supervision by a physiotherapist 6 times during the intervention period.~The patient is strongly encouraged to do the assigned training protocol at home 3 times a week. The supervised physiotherapy consists of introduction, review and progression of the assigned exercises. In addition, the patient will receive education and guidance in daily use of the arm and appropriate load on the shoulder.
Study: NCT06318455

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing exercise
Description: For 12 weeks they will do kumbaka breathing exercise for 5 minutes twice a day in the morning and evening
Study: NCT06147570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10365 capsules
Description: HS-10365 will be administered orally twice daily until the occurrence of disease progression, unacceptable adverse events, withdrawal of consent, death or the end of the study.
Study: NCT05112627

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo blood collection
Study: NCT05183048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [89Zr]Panitumumab Tracer
Description: All patients entered into the study will have \[89Zr\]Panitumumab-PET/MRI imaging.
Study: NCT04972929

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation
Description: Diversified (i.e. crossed bilateral hypothenar contact) chiropractic technique will be administered at levels of identified spinal joint restriction/dysfunction (derived from thoracic spine x-rays, static and motion palpation, and confirmed or provoked localized tenderness in paraspinal soft tissues).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Spinal Manipulation
Description: Sham-SM will be delivered by setting the expansion control knob on an Activator II (Activator Methods®, Phoenix AZ) device to the zero position (off; no thrust) and placed onto the dorsal thumb surface of the clinician (no actual instrument contact with study participant). At a setting of zero, no excursion of the Activator II stylus occurs, despite the device delivering an audible clicking sound, with no biomechanical force being imparted to the participant.
Study: NCT05630144

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HomeMed
Description: The HomeMed intervention is a multidisciplinary deprescribing intervention including home visits and team-based telehealth communication (optional). The components included in the HomeMed intervention include home medication review, medication education and provision of tools to assist the patients with medication administration, assessment of deprescribing targets by a trained geriatric clinical pharmacist, communication with the patient's treating primary care provider about deprescribing recommendation, deprescribing implementation (optional), and deprescribing monitoring (optional). Depending on the patient's treating primary care provider's decision on deprescribing and monitoring, the number of home visits ranges from a minimum of three to more with the entire duration of the intervention ranging from approximately 1 to 3 months.
Study: NCT05555251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI-1607
Description: administered at different doses in Phase I by intravenous infusions every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI-1607
Description: administered at the recommended dose in Phase 2a by intravenous infusions every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: administered at 8mg/kg for the first infusion and at 6mg/kg in subsequent infusions by intravenous infusions every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: administered at 8mg/kg for the first infusion and at 6mg/kg in subsequent infusions by intravenous infusions every 3 weeks.
Study: NCT05533775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Participants will receive intravenous (IV) obinutuzumab pretreatment on Days 1 and 2 of Cycle 1 (Cycle length = 21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Participants will receive intravenous (IV) obinutuzumab pretreatment on Days 1 and 2 of Cycle 1 (Cycle length = 21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Arm A: Participants will receive IV glofitamab on Days 8 and 15 of Cycle 1, then on Day 1 of Cycles 2 and 3~Arm B: Participants will receive IV glofitamab on Days 8 and 15 of Cycle 1, then on Day 1 of each cycle thereafter~(Cycle length = 21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Arm A: Participants will receive IV glofitamab on Days 8 and 15 of Cycle 1, then on Day 1 of Cycles 2 and 3~Arm B: Participants will receive IV glofitamab on Days 8 and 15 of Cycle 1, then on Day 1 of each cycle thereafter~(Cycle length = 21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants will receive IV rituximab on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Participants will receive IV ifosfamide on Days 3, 4, and 5 of cycle 1 and on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Participants will receive IV carboplatin on Days 3, 4, and 5 of cycle 1 and on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Participants will receive IV etoposide on Days 3, 4, and 5 of cycle 1 and on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS) events

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS) events
Study: NCT06283719

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZG006
Description: ZG006 will be administered as an intravenous (IV) infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZG006
Description: ZG006 will be administered as an intravenous (IV) infusion.
Study: NCT04908176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avapritinib
Description: avapritinib tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: midazolam syrup
Study: NCT05236114

Intervention type: OTHER
Intervention: Observation
Description: No intervention

Intervention type: OTHER
Intervention: Observation
Description: No intervention
Study: NCT06578156

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal High Flow Cannula
Description: High flow nasal cannula is a device that provides heated and humidified high flow gases. In-person. Depending on participant's availability, up to 6 times

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal High Flow Cannula
Description: High flow nasal cannula is a device that provides heated and humidified high flow gases. In-person. Depending on participant's availability, up to 6 times

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Low Flow Cannula
Description: Low flow nasal cannula is a device that provides low flow gases. In-person. Depending on participant's availability, up to 6 times

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Low Flow Cannula
Description: Low flow nasal cannula is a device that provides low flow gases. In-person. Depending on participant's availability, up to 6 times
Study: NCT06650995

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: exercise intervention will consist of supervised, home-based, combined training with elements of endurance, resistance and respiratory training
Study: NCT06072287

Intervention type: DIAGNOSTIC_TEST
Intervention: Living with LTC Questionnaire
Description: A questionnaire that will ask about demographic information, mental wellbeing and distress related to chronic illness.
Study: NCT06495450

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omnidirectional Virtual Reality and Treadmill Training
Description: Omni-VR forest scenario developed by our team involving real-life dual task walking and dynamic balance activities (ie. stepping over obstacles, and managing distractions) will be used for treatment group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Exercise
Description: A traditional exercise program including strengthening and unidirectional treadmill activities for the same duration will be completed in control group.
Study: NCT04775225

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: denervation of the obturator and femoral genicular branches by Lidocaine 2 %

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: an equivalent amount of saline will be injected subcutaneously in 2 points similar to the active group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid
Description: Intra-articular injection of 80mg of triamcinolone
Study: NCT04710888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: use of basil extract gel in treatment of aphthus ulcer
Description: This study aimed to evaluate the efficacy of basil extract (Ocimum basilicum) in the treatment of aphthous ulcers

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: muco adhesive placebo gel
Description: mucoadhesive gel without drug which was used as placebo (contains tragacanth gum, alcohol, sodium benzoate, and distilled water) 4 times per day

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: no treatment
Description: (i) had underlying systemic disease(s) or a history of immunologic disorder(s); (ii) were taking immunomodulatory agents or systemic nonsteroidal anti-inflammatory drugs \< 1 month before study commencement; (iii) are smokers; (iv) are pregnant; (v) had a history of abusing drugs or alcohol; (vi) could not provide written informed consent.
Study: NCT05555667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate
Description: Sedation drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol. Sedation drug
Study: NCT05145335

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autoregulated Blood Flow Restriction Cuff (smart-cuff pro devices, acting as pressurized tourniquet) combined with low load strength training
Description: This group will undergo 2 sessions consisting of a low load leg extension exercise combined with a pressurized tourniquet which autoregulates so when the quadriceps muscle contracts, the total amount of pressure doesn't increase, as the tourniquet will lower the pressure to keep the total amount of pressure constant.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-autoregulated blood flow restriction cuff ((smart-cuff pro devices, acting as pressurized tourniquet) combined with low load strength training)
Description: This group will undergo 2 sessions consisting of a low load leg extension exercise combined with a pressurized tourniquet which does not autoregulate so when the quadriceps muscle contracts, the total amount of pressure will increase, as the tourniquet will not lower the pressure to keep the total amount of pressure constant.
Study: NCT06512337

Intervention type: DRUG
Intervention: Deucravacitinib
Description: As per product label
Study: NCT04337255

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Dietary intervention ( MIND Diet)
Description: The MIND diet is a hybrid of the Mediterranean and DASH diets but with selected modifications based on the most compelling evidence in the diet dementia field. The MIND diet has the same basic components of the DASH and Mediterranean diets, such as emphasis on natural plant based foods and limited animal and high saturated fat foods, but uniquely specifies green leafy vegetables and berries as well as food component servings that reflect the nutrition dementia evidence.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral Usual Care Diet Intervention
Description: The Usual Care diet is comprised of both westernized (e.g. Steak, Mac n Cheese) and healthy ( veggie chili) food components
Study: NCT06500676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFH375
Description: GFH375 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.
Study: NCT06540768

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Normothermia Group
Description: Maintenance of a body temperature between 35 and 37 degrees Celsius using conservative and pharmacological interventions for 72 hours.
Study: NCT06540547

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MomMA Intervention
Description: Parents will receive sessions of CBT-based behavioral intervention with components targeted specifically towards expectant parents with ADHD. Treatment will be delivered by therapists embedded in OB care settings. The number and specific content of sessions will be determined based on community partner feedback.
Study: NCT06607172

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oral irrigator
Description: water flosser device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: oral irrigator
Description: water flosser and 0.075% CPC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetylpyridinium Chloride (CPC)
Description: Cetylpyridinium 0.075%
Study: NCT06678945

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bar-Clip attachment
Description: The 2 implants will be connected with bar attachments while the denture will be retained over the bar using clip.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bar- OT Equator attachment
Description: The 2 implants will be connected with bar attachments while the denture will be retained over the bar using the OT Equator.
Study: NCT06065735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: Paroxetine will be administered